Not a good buy right now: price is breaking down below near-term support (trading below S1 0.578 in pre-market at ~0.539) with bearish momentum still expanding.
No Intellectia edge today: both AI Stock Picker and SwingMax show no active buy signal, so there’s no strong tactical reason to step in.
With an impatient trading profile, the setup favors avoiding/ exiting rather than trying to catch an oversold bounce that lacks a catalyst.
Momentum: MACD histogram -0.0321 and negatively expanding → selling pressure is strengthening, not stabilizing.
RSI(6): 23.787 (oversold territory). This can produce short bounces, but oversold can stay oversold in downtrends.
Key levels: Pivot 0.769 (well above price = weak structure). Support S1 0.578 already lost; next support S2 0.46. Resistance levels overhead at R1 0.96 and R2 1.078 are far away.
Pattern-based short-horizon odds: modeled expectation leans slightly negative (next day -4.1%, next week -2.1%), with only marginally positive next-month drift (+0.52%).
Positive Catalysts
Gross margin improved to 31.32% (+82.94% YoY), which is a quality-of-revenue improvement if it holds.
Oversold RSI may attract short-term mean-reversion buyers (bounce potential), but this is tactical and not confirmed by signals.
Neutral/Negative Catalysts
increases risk of a continuation move toward S2 (0.46).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 1,651,787, down -31.12% YoY (top-line contraction).
Net income: -221,304, down -61.93% YoY (loss widened versus prior year period per provided metric).
EPS: -0.07, down -74.07% YoY (earnings trend deteriorating).
Gross margin: 31.32%, up +82.94% YoY (the main bright spot, but not yet translating into profitability).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data provided, so there’s no visible Wall Street trend to lean on.
Pros view (in absence of coverage): margin improvement could be a positive narrative if revenue stabilizes.
Cons view: declining revenue and worsening EPS typically keep professional sentiment cautious and reduce appetite to buy into downtrends.
Wall Street analysts forecast IVDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVDA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast IVDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVDA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
